Developer docs
API playgroundTry for free, no card

Search company profiles

VaxEquity

Full company profile

uuid0004amp

Namestring
VaxEquity
Websiteurl
vaxequity.com
Company typeenum
Private
Founded yearint
2020
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
RNA vaccine development, self-amplifying RNA therapeutics, biopharmaceutical research, saRNA technology platform, influenza vaccine candidate
Industry1 code
PRIMARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceuticals / RNA Therapeutics
Social media profiles1 record
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

VaxEquity is a biotechnology company developing RNA-based vaccines and therapeutics using proprietary self-amplifying RNA (saRNA) technology. The company's core focus is optimizing scalable saRNA production to enable rapid clinical development and improve global vaccine availability, with an active candidate influenza vaccine advancing through manufacturing process optimization in collaboration with CPI, supported by an Innovate UK grant.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Rapid clinical development enabled through optimized saRNA production processes
Product overview1 text field

VaxEquity is a biotechnology company developing RNA-based vaccines and therapeutics. Their core technology focuses on self-amplifying RNA (saRNA) for vaccine development. The company is working on an influenza vaccine candidate with manufacturing optimization support from CPI, funded by an Innovate UK grant of approximately £700K. Their pipeline centers on saRNA production to improve global vaccine availability.

Product and service2 records
1RNA Vaccines and Therapeutics
CategoryBiopharmaceuticals / RNA Therapeutics
2Influenza Vaccine Candidate
CategoryVaccines
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-06-05
Description

VaxEquity partnered with CPI (Centre for Process Innovation) to advance manufacturing processes for RNA vaccines and therapeutics. The collaboration focuses on optimizing saRNA production conditions for a candidate influenza vaccine to enable rapid clinical development and improve global vaccine availability. This partnership is supported by an Innovate UK grant of approximately £700K.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Arcturus is the most direct peer; it is a clinical-stage company specializing in self-amplifying mRNA (saRNA) vaccine and therapeutic platforms with a comparable technology base to VaxEquity's saRNA focus.

TypeDirect peer
Description

CureVac develops mRNA-based vaccines and therapeutics across infectious disease and oncology, competing in the same RNA modality and target indications as VaxEquity, with broader pipeline scale.

TypeBroad incumbent
Description

Moderna is the dominant commercial mRNA vaccine and therapeutics company and has publicly advanced saRNA programs; it operates as the broad incumbent whose scale, manufacturing, and clinical data set the competitive bar for emerging RNA players.

TypeBroad incumbent
Description

BioNTech is a leading mRNA therapeutics and vaccine company with infectious-disease and oncology programs; it competes for the same influenza-vaccine market VaxEquity targets and is a likely partner or acquirer of niche RNA platforms.

5Translate Bio (Sanofi)
TypeBroad incumbent
Description

Translate Bio, acquired by Sanofi, focuses on mRNA therapeutics for infectious disease and rare diseases and represents an established mRNA platform relevant to VaxEquity's manufacturing and clinical-development positioning.

6Ethris
TypeEmerging player
Description

Ethris is a clinical-stage mRNA therapeutics company with a focus on respiratory and rare-disease applications; it overlaps with VaxEquity on modality and respiratory delivery but is at a later clinical stage.

TypeEmerging player
Description

eTheRNA is a Belgium-based mRNA and saRNA immunotherapies developer targeting infectious disease and oncology; it is a comparable emerging European peer using self-amplifying RNA constructs.

TypeEmerging player
Description

Scancell is a UK-based clinical-stage biotech developing DNA and mRNA-based vaccines for cancer and infectious disease; it overlaps with VaxEquity's UK base and nucleic-acid vaccine modality.

TypeOthers
Description

Touchlight is a UK-based CDMO with enzymatic DNA and nucleic-acid manufacturing capabilities serving vaccine developers; it is comparable as an enabling manufacturing-services peer rather than a direct competitor.

TypeOthers
Description

CPI is a UK process-innovation Catapult and current VaxEquity co-development partner for saRNA manufacturing scale-up; it is included as an ecosystem/partner enabler rather than a competing product company.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat1 record

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

VaxEquity

Biopharmaceuticals / RNA Therapeuticsvaxequity.com

VaxEquity firmographics

Firmographics
Name
VaxEquity
Website
https://vaxequity.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

VaxEquity industry classification

Industry
Product category
Biopharmaceuticals / RNA Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

Keywords

  • RNA vaccine development
  • Self-amplifying RNA therapeutics
  • Biopharmaceutical research
  • SaRNA technology platform
  • Influenza vaccine candidate

Where VaxEquity is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Markets served

VaxEquity business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

VaxEquity product offering

Product offering

Core offering

VaxEquity is a biotechnology company developing RNA-based vaccines and therapeutics using proprietary self-amplifying RNA (saRNA) technology. The company's core focus is optimizing scalable saRNA production to enable rapid clinical development and improve global vaccine availability, with an active candidate influenza vaccine advancing through manufacturing process optimization in collaboration with CPI, supported by an Innovate UK grant.

Product overview

VaxEquity is a biotechnology company developing RNA-based vaccines and therapeutics. Their core technology focuses on self-amplifying RNA (saRNA) for vaccine development. The company is working on an influenza vaccine candidate with manufacturing optimization support from CPI, funded by an Innovate UK grant of approximately £700K. Their pipeline centers on saRNA production to improve global vaccine availability.

Differentiator

Problem solved

Functional benefit

Products and services

  • RNA Vaccines and Therapeutics
  • Influenza Vaccine Candidate

Quantifiable outcome

  • Rapid clinical development enabled through optimized saRNA production processes

Companies that use VaxEquity

Customer profile

Segments1 record

Ideal customer profiles2 records

VaxEquity technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

VaxEquity partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • CPI (Centre for Process Innovation)coreStrategic or Co-development Partner · 5 June 2023VaxEquity partnered with CPI (Centre for Process Innovation) to advance manufacturing processes for RNA vaccines and therapeutics. The collaboration focuses on optimizing saRNA production conditions for a candidate influenza vaccine to enable rapid clinical development and improve global vaccine availability. This partnership is supported by an Innovate UK grant of approximately £700K.

Scale indicators1 record

Recent moves4 records

Expansion highlights3 records

VaxEquity competitors and assessment

Company assessment

Direct peers

  • Arcturus Therapeutics: Arcturus is the most direct peer; it is a clinical-stage company specializing in self-amplifying mRNA (saRNA) vaccine and therapeutic platforms with a comparable technology base to VaxEquity's saRNA focus.
  • CureVac: CureVac develops mRNA-based vaccines and therapeutics across infectious disease and oncology, competing in the same RNA modality and target indications as VaxEquity, with broader pipeline scale.

Broad incumbents

  • Moderna: Moderna is the dominant commercial mRNA vaccine and therapeutics company and has publicly advanced saRNA programs; it operates as the broad incumbent whose scale, manufacturing, and clinical data set the competitive bar for emerging RNA players.
  • BioNTech: BioNTech is a leading mRNA therapeutics and vaccine company with infectious-disease and oncology programs; it competes for the same influenza-vaccine market VaxEquity targets and is a likely partner or acquirer of niche RNA platforms.
  • Translate Bio (Sanofi): Translate Bio, acquired by Sanofi, focuses on mRNA therapeutics for infectious disease and rare diseases and represents an established mRNA platform relevant to VaxEquity's manufacturing and clinical-development positioning.

Emerging players

  • Ethris: Ethris is a clinical-stage mRNA therapeutics company with a focus on respiratory and rare-disease applications; it overlaps with VaxEquity on modality and respiratory delivery but is at a later clinical stage.
  • eTheRNA Immunotherapies: eTheRNA is a Belgium-based mRNA and saRNA immunotherapies developer targeting infectious disease and oncology; it is a comparable emerging European peer using self-amplifying RNA constructs.
  • Scancell: Scancell is a UK-based clinical-stage biotech developing DNA and mRNA-based vaccines for cancer and infectious disease; it overlaps with VaxEquity's UK base and nucleic-acid vaccine modality.

Others

  • Touchlight (now Lonza DNA): Touchlight is a UK-based CDMO with enzymatic DNA and nucleic-acid manufacturing capabilities serving vaccine developers; it is comparable as an enabling manufacturing-services peer rather than a direct competitor.
  • CPI (Centre for Process Innovation): CPI is a UK process-innovation Catapult and current VaxEquity co-development partner for saRNA manufacturing scale-up; it is included as an ecosystem/partner enabler rather than a competing product company.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat1 record

Key risks5 records

Key highlights5 records

Customer concentration

VaxEquity social profiles

Digital presence

VaxEquity financial estimates

Financial estimate

Revenue estimate

Valuation estimate

VaxEquity leadership team

Management profile

Number of profiles

VaxEquity funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

VaxEquity M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about VaxEquity

What does VaxEquity do?

VaxEquity is a biotechnology company developing RNA-based vaccines and therapeutics using proprietary self-amplifying RNA (saRNA) technology. The company's core focus is optimizing scalable saRNA production to enable rapid clinical development and improve global vaccine availability, with an active candidate influenza vaccine advancing through manufacturing process optimization in collaboration with CPI, supported by an Innovate UK grant.

Is VaxEquity a public or private company?

VaxEquity is a private company. It is classified as venture growth investor backed and is currently operating.

When was VaxEquity founded?

VaxEquity was founded in 2020. It employs 1 to 10 people.

Where is VaxEquity based?

VaxEquity is headquartered in Cambridge, United States, in the North America region.

Who are VaxEquity's main competitors?

Direct peers on record are Arcturus Therapeutics and CureVac. Broad incumbents are Moderna, BioNTech and Translate Bio (Sanofi). Emerging players are Ethris, eTheRNA Immunotherapies and Scancell. Others are Touchlight (now Lonza DNA) and CPI (Centre for Process Innovation).

Does VaxEquity have an API?

No public API is recorded for VaxEquity.

What industry is VaxEquity in?

VaxEquity's product category is Biopharmaceuticals / RNA Therapeutics. Its primary akta.pro industry code is HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ZapierVaxEquity and CPI Announces Innovate UK Grant to Accelerate Next Generation RNA Vaccines and TherapeuticsVaxEquity and the Cambridge Protein Innovations (CPI) centre have secured a £700,000 grant from Innovate UK to advance the manufacturing process for self-amplifying RNA vaccines. The collaborative project aims to optimize scalability for saRNA production, specifically targeting an influenza vaccine candidate for rapid progression into clinical trials. This initiative seeks to establish an optimized manufacturing process that could facilitate the development of future RNA-based therapeutics.GlobeNewswireVaxEquity and CPI Announces Innovate UK Grant to Accelerate Next Generation RNA Vaccines and TherapeuticsVaxEquity and CPI received a £700K Innovate UK grant to advance manufacturing of self-amplifying RNA vaccines. The project aims to scale saRNA production and progress a candidate influenza vaccine into clinical trials, addressing flu's 11,000 annual deaths in England.GlobeNewswireVaxEquity and CPI Announces Innovate UK Grant to Accelerate Next Generation RNA Vaccines and TherapeuticsVaxEquity and the Centre for Process Innovation (CPI) announced a £700K grant from Innovate UK to accelerate the manufacturing process for next-generation self-amplifying RNA vaccines. The collaborative project aims to optimize scalability for saRNA production, with plans to advance an influenza vaccine candidate into clinical trials. This initiative seeks to address annual flu mortality in England by improving the efficiency of RNA transcription in batch processes.BioSpaceVaxEquity and CPI Announces Innovate UK Grant to Accelerate Next Generation RNA Vaccines and TherapeuticsVaxEquity and the Centre for Process Innovation (CPI) have secured a £700,000 grant from Innovate UK to advance the manufacturing process for self-amplifying RNA vaccines. The collaborative project aims to optimize scalability for saRNA production, with specific plans to progress a candidate influenza vaccine into clinical trials. This development seeks to address the high mortality associated with seasonal flu in England by establishing an optimized manufacturing process.AstrazenecaOur approach to nucleotide-based therapeuticsThe article outlines a strategic approach to developing nucleotide-based therapeutics, including ASOs, siRNA, mRNA, and saRNA, through internal research and external collaborations. Key partnerships involve Ionis Pharmaceuticals for ASO development, Silence Therapeutics for siRNA, VaxEquity for saRNA, and Gatehouse Bio for AI-driven RNA mutation identification. The company is also advancing targeted delivery systems using lipid nanoparticles and GalNAc conjugates to treat diseases such as NASH, cardiovascular conditions, and heart failure.PR NewswireVaxEquity Announces Strategic Collaboration with AstraZeneca to Commercialise Self-Amplifying RNA PlatformVaxEquity has announced a strategic collaboration with AstraZeneca to develop and commercialize its self-amplifying RNA platform, with VaxEquity eligible to receive up to $195 million in development, approval, and sales-based milestones plus mid-single digit royalties per drug target. AstraZeneca will provide R&D funding and has the option to collaborate on up to 26 drug targets, while also taking board seats through Tyrell Rivers and Anders Holmén. Morningside Ventures co-invested alongside AstraZeneca in the upfront equity round, and the long-term collaboration aims to optimize VaxEquity's saRNA technology for therapeutic applications beyond traditional mRNA vaccines.AstrazenecaAstraZeneca to discover and develop self-amplifying RNA therapeutics in new collaboration with VaxEquityAstraZeneca has entered a strategic collaboration with VaxEquity for the discovery, development, and commercialisation of a self-amplifying RNA (saRNA) therapeutics platform originally developed at Imperial College London. Under the agreement, AstraZeneca will provide R&D funding, with potential milestones of up to $195 million plus mid-single digit royalties per programme across up to 26 drug targets. The saRNA platform offers advantages over conventional mRNA by self-amplifying to express proteins for longer periods, potentially enabling lower dosing, reduced costs, and broader therapeutic applications.